MiNK Therapeutics develops therapies for cancer and other diseases.
INKT's iNKT cells target conserved lipid antigens rather than mutable peptides, enabling off-the-shelf allogeneic cell therapy with lower rejection risk and manufacturing costs, representing a third immune branch with breakthrough potential in dense tumors.